MiMedx Group Inc.
A ventilator Covidien’s Nellcor arm attracts another Class I recall | Regulatory news for the week of January 12, 2015
BD, CFN settle merger lawsuits | Medtech legal news for the week of January 12, 2015
Zimmer signs allograft distro agreement with MiMedx
MiMedx boosts Medicare reimbursement, offers $5M in shares
MiMedx inks allograft deal with Medtronic
Venture capital survey reveals expectations gap between CEOs, VCs | Wall Street Beat
A survey of 158 CEOs and 216 venture capital firms revealed a large gap between the chief executives’ wish list for potential backers and what VCs think the CEOs want.
Startup CEOs in the IT and life science industries want VCs who are "entrepreneur friendly" and "collaborative" without being too hands-on in their approach, according to a survey sponsored by the National Venture Capital Assn.
Jawbone agrees to pony up more than $100M for BodyMedia’s wearable sensors | Wall Street Beat
Jawbone agreed to acquire BodyMedia, reportedly for more than $100 million, in a bid to expand its footprint in the wearable technology market.
San Francisco-based Jawbone did not disclose the deal’s value, but Reuters, citing "a person familiar with the matter," reported that it’s worth "north of $100 million."
Pittsburgh-based BodyMedia’s roughly 60 employees will "join Jawbone’s existing team," according to a press release.
InspireMD raises $23M for MGuard stent | Wall Street Beat
Gingrich’s health consulting group goes under | Wall Street Beat
The Center for Health Transformation, a health care think tank launched by GOP presidential hopeful Newt Gingrich, filed for Chapter 7 bankruptcy this week, listing liabilities of between $1 million and $10 million that it says it can’t repay.
The organization’s assets, which it listed in court filings at between $50,000 and $100,000, will be liquidated and the business may subsequently close.
Analyst: CRM market “bad as it’s ever been” | Wall Street Beat
The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.